
April 21 (Reuters) - Immunovant Inc IMVT.O:
IMMUNOVANT ANNOUNCES NEXT PHASE OF GROWTH WITH ROIVANT INCLUDING CHANGES TO ITS LEADERSHIP TEAM AND ADDITIONAL INDICATIONS SJÖGREN’S DISEASE (SJD) AND CUTANEOUS LUPUS ERYTHEMATOSUS (CLE) FOR IMVT-1402
IMMUNOVANT INC - ERIC VENKER APPOINTED AS CEO OF IMMUNOVANT
IMMUNOVANT INC - TIAGO GIRAO APPOINTED AS CFO OF IMMUNOVANT
IMMUNOVANT INC - IND CLEARED FOR IMVT-1402 IN SJD, STUDY TO INITIATE SUMMER 2025
IMMUNOVANT INC - CURRENT CASH BALANCE PROVIDES RUNWAY THROUGH GRAVES’ DISEASE READOUT IN 2027